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Edited by Christian GriesingerAbstract The interaction of immunoglobulin E (IgE) with its
cellular receptor FceRIa is a central regulator of allergy. Struc-
tural studies have identiﬁed the third domain (Ce3) of the con-
stant region of epsilon heavy chain as the receptor binding
region. The isolated Ce3 domain is a ‘‘molten globule’’ that be-
comes structured upon binding of the FceRIa ligand. In this
study, ﬂuorescence and nuclear magnetic resonance spectrosco-
pies are used to characterise the role of soluble FceRIa in the
folding of the monomeric Ce3 domain of IgE. Soluble FceRIa
is shown to display characteristic properties of a catalyst for
the folding of Ce3, with the rate of Ce3 folding being dependent
on the concentration of the receptor.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Allergic diseases aﬀect approximately one third of the gen-
eral population [1]. The interaction between immunoglobulin
E (IgE) and its high aﬃnity receptor (FceRI) is absolutely
required for the initiation of the allergic response in vivo
[2]. Binding of a multivalent antigen to the IgE–FceRI com-
plex on the surface of classic cells of anaphylaxis immedi-
ately initiates signal transduction cascades that underlie the
type I hypersensitivity reaction which, in the severest case,
can result in death [3,4]. A more detailed characterisation
of the interaction between IgE and FceRI will be of great
pharmacological value in the process of structure-based de-
sign of potential preventative therapies for allergic diseases.
IgE is a heterotetramer of two heavy chains and two light
chains, organised into discrete globular domains containing
the immunoglobulin (Ig) fold (reviewed in [5,6]). Each of these
Ig domains is comprised of around 110 amino acids, folded
into a b-sheet sandwich of the C-type topology. The interac-Abbreviations: 7-AW, 7-azatryptophan; ANS, 8-anilinonaphthalene-1-
sulfonate; Ce3, the third constant domain of IgE; FceRI, high aﬃnity
receptor for IgE; HSQC, 1H-15N-heteronuclear single quantum coher-
ence; IgE, immunoglobulin E; IgG, immunoglobulin G; IPTG, iso-
propyl b-D-thiogalactoside; NMR, nuclear magnetic resonance; PBS,
phosphate-buﬀered saline; sFceRIa, the extracellular domains of the
a-chain of FceRI; Tm, melting temperature
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on IgE have been localised to the third constant domains
(Ce3), both by site-directed mutagenesis [7] and, more recently
and deﬁnitively through the determination of the crystal struc-
ture of the Ce3–4 dimer in complex with sFceRIa [8]. The crys-
tal structure of the complex also conﬁrms and explains the
stoichiometry of the Ce3–4:sFceRIa interaction, where the
two Ce3 domains contained within one IgE molecule interact
with one molecule of sFceRIa.
An isolated monomeric Ce3 domain has been expressed and
puriﬁed and, despite lacking the native Ig-fold structure, was
shown by surface plasmon resonance to be competent for
sFceRIa binding, with an aﬃnity constant KA = 5 · 106 M1
[9]. We previously characterised this monomeric Ce3 domain,
conﬁrming its capacity for interaction with sFceRIa using ﬂuo-
rescence and nuclear magnetic resonance (NMR) spectrosco-
pies [10]. We observed a structural transition in the Ce3
domain, from ‘‘molten globule’’ to folded tertiary structure,
via the dissociation of the hydrophobic ﬂuorescent probe 8-
anilinonaphthalene-1-sulfonate (ANS) on interaction with
sFceRIa.
It has been suggested that around 30% of eukaryotic pro-
teins contain regions of intrinsic disorder [11]. Such disordered
regions allow modulation of speciﬁcity and aﬃnity of the pro-
teins interactions and have been observed in regulatory pro-
cesses such as the cell cycle [12]. Thermal stability can give
an indication of the presence of disordered regions in a protein;
such studies have indicated that whole IgE contains a region of
disorder, mapping to the region responsible for binding to
sFceRIa [13]. It has been shown that often these regions of dis-
order adopt a more ordered structure on interaction with a
binding partner, suggesting a common link between folding
and binding within proteins [14–16]. The process by which a
protein folds can be described by a downhill energy search to-
wards the lowest energy conformation [17]. Many proteins
cannot reach their folded state without assistance from one
or more chaperone molecules [18–20]. These chaperones act
to prevent incorrect interactions and in conjunction with other
folding factors allow the protein to overcome local energy bar-
riers to reach their ﬁnal low-energy folded state. A number of
classic folding systems have been investigated thoroughly, both
theoretically and experimentally, and have been used to deﬁne
principles that can be used in the understanding of protein
folding behaviour [21,22]. More recently, similar approaches
have been applied to describe the energetics of protein–ligand
interactions [23].
We have used speciﬁc tryptophan labelling and ﬂuorescence
spectroscopy in order to investigate the stoichiometry of the
folding of the Ce3 domain of IgE upon interaction with sFceR-blished by Elsevier B.V. All rights reserved.
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rescent label, 7-azatryptophan (7-AW), independently indicate
the catalytic nature of sFceRIa in promoting the folding of the
Ce3 domain, and the determination of the rate of folding. The
interaction of Ce3 with sFceRIa was also investigated using
NMR spectroscopy. Observation of the interaction by NMR
gives an insight into the folding of Ce3 with the potential for
atomic resolution, permitting the identiﬁcation of groups of
residues that appear to fold with similar kinetic characteristics.
This evidence would suggest diﬀerent regions of the Ce3 struc-
ture fold, using sFceRIa as a catalyst, at diﬀerent rates rather
than by a simple two-state folding mechanism.2. Materials and methods
2.1. Expression and puriﬁcation of sFceRIa
The production of a soluble fragment of human sFceRIa (Val1 to
Lys176) for mammalian expression in the mouse myeloma cell line
NS0 [24] and subsequent cloning and expression of a shorter construct
(Val1 to Ala172) in yeast Pichia pastoris have been detailed previously
[24,25]. The pPICZa vector (Invitrogen) containing the sFceRIa
(Val1 to Ala172) construct with an N-terminal polyhistidine tag was
transformed into P. pastoris strain SMD1168H. Fermentative growth
of the P. pastoris clone was performed according to the manufacturer’s
guidelines (Invitrogen). sFceRIa was puriﬁed by hydrophobic interac-
tion chromatography and subsequently by aﬃnity chromatography on
a Ni2+ column as described previously [10]. The protein concentration
was determined spectrophotometrically using an extinction coeﬃcient
at 280 nm of 2.56 for a 1 mg/ml solution in a cuvette of pathlength
1 cm [25].
2.2. Expression of recombinant Ce3
The Ce3 fragment (Cys328 to Ser437), with C328S mutation, pro-
duced by PCR using an IgE-Fc cDNA clone isolated from U266 cells,
was sub-cloned into NdeI and BamHI cloning sites of pET5a expres-
sion vector (Novagen) as described previously [9]. Subsequently the
Ce3 fragment was isolated from the pET5a clone by PCR and sub-
cloned into the pET28a expression vector (Novagen) as described [10].
Recombinant Ce3 was expressed in E. coli host strain BL21(DE3).
Transformants were grown in LB or M9 media with addition of
30 lg/ml kanamycin at 37 C with aeration. 15N-labelled samples were
prepared in M9 media with the addition of 1.0 g/l 15NH4Cl. Recombi-
nant protein expression was induced by addition of 1 mM isopropyl b-
D-thiogalactoside (IPTG). Rifampicin was added to the cultures 40
min after induction had been started, to a ﬁnal concentration of
50 lg/ml as described [26]. Protein expression was allowed to continue
for 20 h following induction.
2.3. Incorporation of 7-AW into recombinant Ce3
For speciﬁc 7-AW labelling of Ce3, cultures were grown as described
above, to A600 of 0.8 and then 1 g/l glyphosate (Sigma) was added to
inhibit aromatic amino acid synthesis, along with 50 mg/l phenylala-
nine and tyrosine (Melfords Laboratories Ltd.) and 36 mg/l 7-AW
(Sigma). Cultures were incubated for 1 h before inducing protein
expression with 1 mM IPTG. Rifampicin was added to the cultures
40 min after induction of protein expression to a ﬁnal concentration
of 50 lg/ml as described [26]. Protein expression was allowed to con-
tinue for 20 h following induction.
2.4. Puriﬁcation of recombinant Ce3
Recombinant Ce3 was refolded and puriﬁed from inclusion bodies
through immobilisation and subsequent elution from a Ni2+ aﬃnity
column as described previously [10]. Recombinant Ce3 was concen-
trated and buﬀer exchanged into phosphate-buﬀered saline (PBS),
pH 5.0. The protein concentration was determined spectrophotometri-
cally using an extinction coeﬃcient at 280 nm of 1.15 for a 1 mg/ml
solution [9] of Ce3 in a cuvette of pathlength 1 cm. There was no reac-
tion between refolded Ce3 and Nbs2 [27] showing that no free sulfhy-
dryl groups were present in the refolded protein.2.5. Fluorescence–ANS titration and timecourse; 7-AW timecourse
The ﬂuorescence spectra of native Ce3 were recorded on a Perkin–
Elmer LS 50 spectroﬂuorimeter at 20 C, using a protein concentration
of 14 lM in PBS at pH 5.0. Protein ﬂuorescence emission was mea-
sured between 300 and 400 nm, following excitation at 290 nm, with
slits set to give 2.5 nm bandpass for excitation and emission. Spectra
were corrected for Raman scattering by the solvent. ANS binding to
Ce3 was studied using an ANS concentration of 17.3 lM. ANS ﬂuo-
rescence emission was measured between 430 and 550 nm, following
excitation at 370 nm, with slits set to give 5.0 nm bandpass for excita-
tion and emission. sFceRIa does not alter ANS ﬂuorescence emission
when added separately to ANS solutions. ANS ﬂuorescence emission
spectra from the Ce3–ANS mixture were recorded after a 10 min incu-
bation period, following the addition of various concentrations of
sFceRIa from 1% (0.14 lM) to 100% (14 lM). For the ANS time-
course 1% (0.14 lM) sFceRIa was incubated with the Ce3–ANS mix-
ture and emission spectra were recorded at various times over 6 h.
Emission spectra were corrected for the eﬀect of dilution by perform-
ing control experiments in which buﬀer alone was added.
Speciﬁc labelling of Ce3 with 7-AW in place of tryptophan causes a
red shift in the ﬂuorescence emission properties of Ce3 [28]. Protein
ﬂuorescence emission of 7-AW labelled Ce3 was monitored between
320 and 500 nm, following excitation at 310 nm, with slits set to give
5.0 nm bandpass for excitation and emission, using a protein concen-
tration of 17.5 lM. 7-AW ﬂuorescence emission was measured follow-
ing addition of sFceRIa at various concentrations; 0.175 lM (1%),
0.875 lM (5%) and 1.75 lM (10%). Emission scans were collected at
120 s time intervals.
2.6. NMR–1H-15N-heteronuclear single quantum coherence (HSQC)
timecourse
A 1 mM sample of 15N-Ce3, with 5% D2O and 0.02% sodium azide,
was transferred into a Shigemi tube (BM-3). Following addition of 1%
(10 lM) sFceRIa, gradient enhanced 1H-15N-heteronuclear single
quantum coherence (HSQC) experiments were recorded at 51 min
intervals. All spectra were recorded on home-built NMR spectrome-
ters with Oxford Instrument magnets, at operating proton frequencies
of 600 MHz. Spectra were recorded at 5 C. The proton carrier fre-
quency was set on water at 4.84 ppm. The spectral width in the direct
1H dimension was 12500 Hz, collected over 1024 points. The spectral
width in the indirect 15N dimension was 1520 Hz, collected over 128
points, with an acquisition time (t1) of 657 ls. In each case 16 scans
were collected. The carrier frequency was set at 120 ppm. All NMR
experiments were carried out in PBS, pH 5.0.3. Results
3.1. Fluorescence–ANS
We have shown previously that recombinant Ce3 exists
alone in solution as a ‘‘molten globule’’, containing near-native
secondary structure but without clearly deﬁned tertiary struc-
ture, and able to bind ANS [10]. The crystal structure of
Ce3–4 dimer in complex with sFceRIa shows deﬁnitively the
1:1 stoichiometry of this interaction [8]. We have used the pro-
pensity of Ce3 to bind ANS to monitor its conformational
state on interaction with sFceRIa, in order to probe the stoi-
chiometry of the reported folding reaction involving mono-
meric Ce3 and sFceRIa. The eﬀect of varying the
concentration of sFceRIa on Ce3 ‘‘foldedness’’ was measured
by recording ANS ﬂuorescence emission spectra after a ﬁxed
incubation period. Fig. 1A shows that increasing sFceRIa
concentration decreases the amount of Ce3 present in the
‘‘molten-globule’’ state. However, it can be clearly seen that
the proportion of Ce3 present as a ‘‘molten-globule’’ is not
linearly dependent on the concentration of sFceRIa; as little
as 2.2% (0.3 lM) sFceRIa is needed to decrease the ﬂuores-
cence intensity of the Ce3-ANS mixture to half its initial value
during the time of this experiment.
Fig. 1. ANS ﬂuorescence emission spectra, following excitation at 370 nm. (A) sFceRIa titration. 0.2 mg/ml Ce3 and 17.3 lM ANS in PBS, pH 5.0,
with various concentrations of sFceRIa added, following incubation for 10 min; (B) Timecourse with 1% sFceRIa added. 14 lM Ce3 and 17.3 lM
ANS in PBS, pH 5.0, with 1% molar ratio of sFceRIa added. In all cases, spectra were normalised to the maximum value of ﬂuorescence emission,
deﬁned as 100 ﬂuorescence units. Each line represents the average of three ﬂuorescence emission scans. A decrease in ANS ﬂuorescence indicates that
ANS is being released from Ce3 as it loses ‘‘molten globule’’ character and acquires deﬁned tertiary structure.
Fig. 2. Fluorescence emission of 7-AW Ce3, following excitation at
310 nm. Three diﬀerent concentrations of sFceRIa – 0.175, 0.875 and
1.75 lM (1%, 5% and 10%, in molar terms, respectively) – were added
to 17.5 lM 7-AW Ce3, and the ﬂuorescence intensity at 381.5 nm was
monitored over time. Fitting was carried out using a simple exponen-
tial decay model (y = yo + Ae
(x/t)). Further analysis assumes a
pseudo-ﬁrst order reaction as the [catalyst] [substrate].
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time-dependence of the Ce3 folding reaction as shown by
ANS release. A ﬁxed concentration 1% (0.14 lM) sFceRIa
was incubated with 14 lM Ce3 and the ANS ﬂuorescence
emission spectra were measured at various intervals over 6
h.Fig. 1B shows that the folding of Ce3 is indeed time-depen-
dent and can occur in the presence of as little as 1% molar ratio
of sFceRIa. This data can be ﬁt to a simple exponential decay
model (y = yo + Ae
(x/t)) yielding a rate constant of 0.0129 ±
0.002 min1 for the folding reaction, as monitored by ANS
release.
3.2. Fluorescence –7-AW
Although ANS binding is an extremely useful probe of Ce3
conformation, ANS ﬂuorescence intensity is highly sensitive
both to light exposure and to slight alterations in salt concen-
tration. An alternative method to monitor the folding of Ce3
by ﬂuorescence spectroscopy, which does not depend on the
presence of an external probe, is through the incorporation
of an intrinsic probe such as 7-AW that modiﬁes the ﬂuores-
cence properties of the protein itself. 7-AW was successfully
incorporated, in place of tryptophan, into recombinant Ce3;
this was indicated by a red shift in the ﬂuorescence emission
properties of labelled Ce3. The presence of the 7-AW label in
Ce3, but not in sFceRIa, allows direct and exclusive monitor-
ing of Ce3 folding following ﬂuorescence excitation at 310 nm.
The eﬀect that the concentration of sFceRIa has on Ce3 fold-
ing was measured in order to establish if sFceRIa behaves as
typical catalyst in the folding reaction. The rate of 7-AW
Ce3 folding was measured on incubation with three diﬀerent
sFceRIa concentrations 0.175 lM (1%), 0.875 lM (5%) and
1.75 lM (10%) (Fig. 2). Even at the highest concentration of
sFceRIa used, pseudo-ﬁrst order kinetics are assumed, as the
Ce3 is present at 10-fold excess over sFceRIa. It can be seen
that the rate of folding of 7-AW Ce3 is clearly dependent on
the concentration of sFceRIa; this appears to have a linear
relationship as would be expected if sFceRIa is acting as a cat-
alyst in the folding of Ce3. The rates of folding observed byANS and through 7-AW labelling are similar (0.0129 ± 0.002
and 0.0106 ± 0.001 min1, respectively) at the same relative
concentration of sFceRIa (Figs. 1B and 2).
3.3. Nuclear magnetic resonance
NMR spectroscopy can be used to monitor directly the fold-
ing of Ce3 on interaction with sFceRIa. 15N-labelling of Ce3,
but not of sFceRIa, allows exclusive observation of amides
within Ce3 and their changes throughout the folding process.
The HSQC of recombinant Ce3 alone is typical of a ‘‘molten
globule’’, sampling a number of diﬀerent conformations and
therefore lacking chemical shift dispersion in both dimensions
(Fig. 3A; shown in red). Following addition of 1% (10 lM)
sFceRIa, a series of seven sequential HSQCs were recorded
Fig. 3. NMR timecourse of 15 N-Ce3 folding. (A) 15N-HSQC overlay. Initial 15N HSQC of 1mM 15N-Ce3 in PBS, pH 5.0, is shown in red. Following
addition of 10 lM sFceRIa (1% on a molar basis), seven consecutive HSQCs were recorded at 51 min time intervals and are shown overlaid. Through
the course of the folding reaction the spectra are shown (earliest ﬁrst) in orange, gold, dark green, light green, cyan, blue and purple; (B) the boxed
region in (A) shown individually for each time point using the same color scheme as above; (C) an overlay of a series of 15N-ﬁltered 1H spectra; the
initial one-dimensional spectra of Ce3 alone is shown at the bottom of the ﬁgure, with successive time points showing the course of the folding
reaction, following the addition of 10 lM sFceRIa (1% molar ratio).
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and, for clarity, one section from the HSQC is shown in a time
series in Fig. 3B. It can be seen that after 6 h (Fig. 3A and B;
shown in purple) the conformation of Ce3 appears to be
approaching the HSQC for the fully folded Ce3 observed pre-
viously [10]. In Fig. 3C a one-dimensional representation of
each of the HSQCs is shown; the initial one-dimensional spec-
tra of Ce3 alone at the bottom of the page, moving up the page
over time and through the course of the folding reaction. The
consequences of the folding reaction on resonances that fall
outside the main cluster of backbone amides (around
8.3 ppm) can be clearly seen using this one-dimensional repre-
sentation.
A more detailed analysis of example individual resonances is
shown in Fig. 4. The side-chain amides of Trp374 and Trp410
initially are present as a single, broad peak but after addition
of 1% sFceRIa the signals separate and resolve into two dis-
tinct peaks (Fig. 4A), indicating that the two tryptophans
are found in diﬀerent chemical environments. The rates of
folding of the two tryptophan side-chains are clearly unequal
(Fig. 4B), suggesting that diﬀerent parts of the Ce3 protein fold
at diﬀerent rates. A more global examination of the NMR data
supports this observation. In this analysis we assign an arbi-
trary label to each peak, in order to follow its intensity changes
during the course of the Ce3 folding reaction. From this anal-
ysis it is possible to divide the peaks broadly into ﬁve groups
based on their rates of appearance and/or disappearance. Such
an observation indicates that the Ce3 folding reaction that we
are observing does not occur by a simple two-state foldingmechanism of the type reported for a number of other protein
folding systems [29,30]. As the full backbone assignment of
folded Ce3 has not yet been determined, it is not possible to
identify which peaks correspond to which Ce3 residue. Such
information would be invaluable in further investigation of
this system – allowing us to localise areas of Ce3 that initially
fold and may be forming a nucleus around which the rest of
the molecule can fold more slowly.4. Discussion
Using the binding of ANS as an indicator of the ‘‘molten
globule’’ character of Ce3, we have been able to monitor indi-
rectly the changes in conformation of Ce3 on interaction with
sFceRIa. We have also been able to monitor the folding of Ce3
by direct methods, using NMR spectroscopy and by speciﬁc
incorporation of the 7-AW label. These direct methods vali-
date the use of the ANS assay and conﬁrm that Ce3 folding
does indeed occur with sFceRIa acting as a catalyst in a con-
centration-dependent manner. From these observations we
propose a folding reaction where Ce3, present as a ‘‘molten
globule’’ alone in solution, can obtain the energy necessary
for overcoming the folding energy barrier through its interac-
tion with sFceRIa. In this system we assume that Ce3 in its
‘‘molten globule’’ state is competent for binding to sFceRIa.
Binding to sFceRIa induces Ce3 folding, and subsequent dis-
sociation of folded Ce3 allows ‘‘recycling’’ of sFceRIa so it
is ready to bind and fold another Ce3. Clearly the rate of
Fig. 4. NMR timecourse of tryptophan folding. (A) Time-resolved HSQCs are displayed for the tryptophan side-chain region. Ce3 has two
tryptophans, whose signals resolve upon addition of the folding catalyst. Time points shown are red (t = 0), orange (t = 51 min), gold (t = 102 min),
dark green (t = 153 min), cyan (t = 204 min), blue (t = 255 min), plum (t = 306 min) and dark purple (t = 357 min). (B) Graphical representation of
the changes in peak intensity over time for the tryptophan side chain peaks, given the arbitrary labels of A and B.
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must occur with the correct energy and orientation to proceed
down the folding pathway. Also, the rate of dissociation of a
bound Ce3/FceRIa complex limits the recycling of the catalyst
in this system. Finally, the folding process is also slowed by
intrinsic and complex energy barriers within the Ce3 structure;
proline isomerization events are likely candidates as limiting
steps.
The rate of Ce3 folding is much slower than typical rates of
protein folding; with folding of many simple proteins being
completed on a millisecond timescale in vitro [31]. The sFceR-
Ia-mediated acceleration of Ce3 folding is also signiﬁcantly
slower than that observed other protein folding catalysts.
Using the rate constants derived in this paper and the pub-
lished KD value for Ce3/sFceRIa [9], we estimate the kcat/KM
value to be approximately 1 · 103 M1 s1, a modest value
in comparison with those measured for peptidyl prolyl isome-
rases, which are roughly 1 · 106 M1 s1 [32]. These markeddiﬀerences underscore the unusual nature of the role played
by IgE’s receptor in the assisted folding of the Ce3 domain.
Acknowledgements: This work was supported by a grant from the
Medical Research Council (to JMM) and a studentship from the
Wellcome Trust (to NEH).References
[1] Ono, S.J. (2000) Molecular genetics of allergic diseases. Annu.
Rev. Immunol. 18, 347–366.
[2] Cookson, W. (1999) The alliance of genes and environment in
asthma and allergy. Nature 402, B5–B11.
[3] Sheets, E.D., Holowka, D. and Baird, B. (1999) Membrane
organization in immunoglobulin E receptor signaling. Curr. Opin.
Chem. Biol. 3, 95–99.
[4] Mekori, Y.A. and Metcalfe, D.D. (2000) Mast cells in innate
immunity. Immunol. Rev. 173, 131–140.
[5] Sutton, B.J. and Gould, H.J. (1993) The human IgE network.
Nature 366, 421–428.
2134 N.E. Harwood et al. / FEBS Letters 580 (2006) 2129–2134[6] Gould, H.J., Sutton, B.J., Beavil, A.J., Beavil, R.L., McCloskey,
N., Coker, H.A., Fear, D. and Smurthwaite, L. (2003) The
biology of IgE and the basis of allergic disease. Annu. Rev.
Immunol. 21, 579–628.
[7] Henry, A.J., Cook, J.P., McDonnell, J.M., Mackay, G.A., Shi, J.,
Sutton, B.J. and Gould, H.J. (1997) Participation of the N-
terminal region of Cepsilon3 in the binding of human IgE to its
high-aﬃnity receptor FcepsilonRI. Biochemistry 36, 15568–
15578.
[8] Garman, S.C., Wurzburg, B.A., Tarchevskaya, S.S., Kinet, J.P.
and Jardetzky, T.S. (2000) Structure of the Fc fragment of human
IgE bound to its high-aﬃnity receptor Fc epsilonRI alpha. Nature
406, 259–266.
[9] Henry, A.J., McDonnell, J.M., Ghirlando, R., Sutton, B.J. and
Gould, H.J. (2000) Conformation of the isolated cepsilon3
domain of IgE and its complex with the high-aﬃnity receptor,
FcepsilonRI. Biochemistry 39, 7406–7413.
[10] Price, N.E., Price, N.C., Kelly, S.M. and McDonnell, J.M. (2005)
The key role of protein ﬂexibility in modulating IgE interactions.
J. Biol. Chem. 280, 2324–2330.
[11] Fink, A.L. (2005) Natively unfolded proteins. Curr. Opin. Struct.
Biol. 15, 35–41.
[12] Iakoucheva, L.M., Brown, C.J., Lawson, J.D., Obradovic, Z. and
Dunker, A.K. (2002) Intrinsic disorder in cell-signaling and
cancer-associated proteins. J. Mol. Biol. 323, 573–584.
[13] Dorrington, K.J. and Bennich, H. (1973) Thermally induced
structural changes in immunoglobulin E. J. Biol. Chem. 248,
8378–8384.
[14] Flynn, G.C., Beckers, C.J., Baase, W.A. and Dahlquist, F.W.
(1993) Individual subunits of bacterial luciferase are molten
globules and interact with molecular chaperones. Proc. Natl.
Acad. Sci. USA 90, 10826–10830.
[15] Hornby, D.P., Whitmarsh, A., Pinarbasi, H., Kelly, S.M., Price,
N.C., Shore, P., Baldwin, G.S. and Waltho, J. (1994) The DNA
recognition subunit of a DNA methyltransferase is predomi-
nantly a molten globule in the absence of DNA. FEBS Lett. 355,
57–60.
[16] Schreiber, G. and Serrano, L. (2005) Folding and binding: an
extended family business. Curr. Opin. Struct. Biol. 15, 1–3.
[17] Clark, P.L. (2004) Protein folding in the cell: reshaping the folding
funnel. Trends Biochem. Sci. 29, 527–534.
[18] Ellis, R.J. and Hemmingsen, S.M. (1989) Molecular chaperones:
proteins essential for the biogenesis of some macromolecular
structures. Trends Biochem. Sci. 14, 339–342.[19] Hartl, F.U. and Hayer-Hartl, M. (2002) Molecular chaperones in
the cytosol: from nascent chain to folded protein. Science 295,
1852–1858.
[20] Frydman, J. (2001) Folding of newly translated proteins in vivo: the
role of molecular chaperones. Annu. Rev. Biochem. 70, 603–647.
[21] Dinner, A.R., Sali, A., Smith, L.J., Dobson, C.M. and
Karplus, M. (2000) Understanding protein folding via free-
energy surfaces from theory and experiment. Trends Biochem.
Sci. 25, 331–339.
[22] Fersht, A.R. and Daggett, V. (2002) Protein folding and
unfolding at atomic resolution. Cell 108, 573–582.
[23] Levy, Y., Cho, S.S., Onuchic, J.N. and Wolynes, P.G. (2005) A
survey of ﬂexible protein binding mechanisms and their transition
states using native topology based energy landscapes. J. Mol.
Biol.s 346, 1121–1145.
[24] Cook, J.P., Henry, A.J., McDonnell, J.M., Owens, R.J., Sutton,
B.J. and Gould, H.J. (1997) Identiﬁcation of contact residues in
the IgE binding site of human FcepsilonRIalpha. Biochemistry
36, 15579–15588.
[25] Mackay, G.A. et al. (2002) Mutagenesis within human
FcepsilonRIalpha diﬀerentially aﬀects human and murine IgE
binding. J. Immunol. 168, 1787–1795.
[26] Lee, K.M., Androphy, E.J. and Baleja, J.D. (1995) A novel
method for selective isotope labeling of bacterially expressed
proteins. J. Biomol. NMR 5, 93–96.
[27] Ellman, G.L. (1959) Tissue sulfhydryl groups. Arch. Biochem.
Biophys. 82, 70–77.
[28] Scott, D.J., Leejeerajumnean, S., Brannigan, J.A., Lewis, R.J.,
Wilkinson, A.J. and Hoggett, J.G. (1999) Quaternary re-arrange-
ment analysed by spectral enhancement: the interaction of a
sporulation repressor with its antagonist. J. Mol. Biol. 293, 997–
1004.
[29] Kragelund, B.B., Robinson, C.V., Knudsen, J., Dobson, C.M.
and Poulsen, F.M. (1995) Folding of a four-helix bundle: studies
of acyl-coenzyme A binding protein. Biochemistry 34, 7217–7224.
[30] Schindler, T., Herrler, M., Marahiel, M.A. and Schmid, F.X.
(1995) Extremely rapid protein folding in the absence of interme-
diates. Nat. Struct. Biol. 2, 663–673.
[31] Dobson, C.M. (2003) Protein folding and misfolding. Nature 426,
884–890.
[32] Kofron, J.L., Kuzmic, P., Kishore, V., Colon-Bonilla, E. and
Rich, D.H. (1991) Determination of kinetic constants for peptidyl
prolyl cis-trans isomerases by an improved spectrophotometric
assay. Biochemistry 30, 6127–6134.
